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Highlights 20 
 Curcumin:cyclodextrin-loaded cellulose based biosynthetic hydrogels were produced. 21 
 These novel hydrogels exhibited haemocompatibility and cellular biocompatibility. 22 
 CUR:HPβCD-loaded-bacterial cellulose showed antibacterial and antioxidant 23 
properties. 24 







Natural bioactive materials with wound healing properties such as curcumin are attracting 27 
interest due to the emergence of resistant bacterial strains. The hydrophobicity of curcumin 28 
has been counteracted by using solubility enhancing cyclodextrins. Hydrogels facilitate 29 
wound healing due to unique properties and 3D network structures which allows 30 
encapsulation of healing agents. In this study, biosynthetic cellulose produced by 31 
Gluconacetobacter xylinus (ATCC 23770) was loaded with water soluble 32 
curcumin:hydroxypropyl-β-cyclodextrin supramolecular inclusion complex produced by a 33 
solvent evaporation method to synthesise hydrogel dressings. The ratios of solvents to 34 
solubilise curcumin and hydroxypropyl-β-cyclodextrin were tested for the production of the 35 
inclusion complex with optimum encapsulation efficacy. The results confirmed that 36 
hydroxypropyl-β-cyclodextrin enhanced the aqueous solubility of curcumin and allowed 37 
loading into bacterial cellulose hydrogels. These hydrogels were characterised for wound 38 
management applications and exhibited haemocompatability, cytocompatability, anti-39 
staphylococcal and antioxidant abilities and therefore support the potential use of the 40 






1. Introduction 42 
Wound healing is a complex physiological process involving sequential yet overlaying 43 
phases [1,2]. Correct clinical management of wounds is vital to minimise complications 44 
during the healing process. The mandatory wound management requirements for all 45 
wounds, no matter whether they are acute or chronic, involve control of infection, cleaning 46 
the wound site and making it free from foreign material and necrotic tissue and the 47 
selection of appropriate wound dressings [3]. Passive dressings e.g. gauze and tulle, 48 
undoubtedly are inexpensive and provide a dry protective barrier, but cannot effectively 49 
interact and respond to changing wound conditions [4]. An ideal dressing not only covers 50 
and protects the affected area, but also optimises the wound environment to facilitate 51 
healing [3,]. George Winter in 1960s established that the optimum moisture at the wound 52 
site increases reepithelialisation and promotes healing [5]. This research revolutionised the 53 
field of wound management, and the focus of wound dressings changed from conventional 54 
dry passive products, to responsive moisture-promoting materials [4,5]. Following these 55 
research findings, a wide range of dressings based on the moist healing concept were 56 
developed with a range of different material compositions.  57 
 
Hydrogels are one of the most promising candidates amongst the category of advanced 58 
moist wound dressings. Hydrogels are composed of over 90% water [6] which is 59 
responsible for their soft and malleable texture. In addition to acting as a barrier, hydrogels 60 
facilitate healing by donating moisture in the case of dry necrotic wounds and absorbing 61 
excessive exudate in the case of exudative wounds. This feature makes them capable of 62 
creating the moist micro-climate between the wound bed and the dressing at the wound 63 
site. Moreover, hydrogels reduce pain as a result of the cooling effect, allows exchange of 64 
gases and can be loaded with antimicrobials and other healing agents [6,7].    65 
 
Several cross-linked natural polymers like alginate, carboxymethyl cellulose, collagen, 66 
chitosan and hyaluronic acid are in use as base materials for hydrogel dressings [1,8]. 67 
Bacterial cellulose (BC), a biosynthetic cellulose based polymeric hydrogel synthesised by 68 
Gluconacetobacter xylinus has attracted wide interest in biomedical applications [9]. Its 69 
hydrophilicity, biocompatibility, non-pyrogenic, high wet strength and transparency are 70 
some of the desirable properties that resulted in its use for fabrication of several 71 











[7,9] with the clinical rationale being to facilitate autolytic debridement. BC’s cross-linked 73 
fibre network structure creates pores which allow impregnation of several healing agents 74 
[7]. 75 
 
Natural products like curcumin (CUR), the curcuminoid present in turmeric, are becoming 76 






mechanisms of action on wound healing [10] and less likely than presently used antibiotics 78 
to develop resistant strains [11]. CUR (diferuloylmethane) (Fig. S1a in the supporting 79 
information) is a naturally derived low molecular weight polyphenolic compound well 80 
known for its pharmacological benefits like, but not limited to, anti-inflammatory, anti-81 
infective and anti-oxidant activities [10,11]. However, its hydrophobicity [11,12] limits its 82 
biological activity for topical delivery for wound management applications.  83 
 
Microencapsulation of medicinal substances in a suitable carrier is a common practice in 84 
pharmaceutics for drug delivery. Encapsulation can be used to protect the active 85 
compound from the external environment, controlling delivery or to enhance the aqueous 86 
solubility of the hydrophobic bioactive materials [13].  Cyclodextrins (CDs) are naturally 87 
occurring cyclic oligosaccharide obtained from starch by enzymatic cyclisation that are 88 
recognized as pharmaceutical adjuvants [14,15]. There are three commonly used native 89 
cyclodextrins: α- cyclodextrin, β- cyclodextrin and γ- cyclodextrin with six, seven and 90 
eight D-glucopyranose units linked by α-1,4 glycosidic bonds respectively. These linkages 91 
of glucopyranose units result in truncated cone structures (Fig. S1b in the supporting 92 
information).  The primary and secondary hydroxyl groups located at the edges are 93 
responsible for hydrophilic exterior surface of CDs. The skeletal carbons (C3 and C5) and 94 
endocyclic acetal oxygen of glucose residues are oriented inside which imparts a 95 
hydrophobic character to the interior CD cavity [16].  The polarity of the CD cavity has 96 
been reported to be similar to an aqueous ethanolic solution [15]. Apart from naturally 97 
occurring CDs, several chemically modified derivatives have been synthesized to improve 98 
the properties (aqueous solubility, toxicological profiles etc.) of native CDs [15,17].  99 
 
There are several studies reported on the enhancement of aqueous solubility of lipophilic 100 
compounds by their inclusion in the CD cavity [12,13,18,19]. This can be achieved by 101 
several techniques like co-precipitation, hot melt extrusion, solvent evaporation, freeze 102 
drying, spray drying, slurry mixing, dry mixing etc. [14]. This study was conducted with 103 
the aim of producing novel biosynthetic hydrogel dressings with healing properties. The 104 
set objective was approached by encapsulation of CUR within hydroxypropyl-β-105 
cyclodextrin (HPβCD) to enhance its aqueous solubility leading to consistent loading in 106 
the biosynthetic BC hydrogel matrix. The potential healing properties and the physical 107 
performance characteristics of the CUR:HPβCD-loaded-BC hydrogels were investigated.  108 
 
Herein, we describe the production of CUR:HPβCD-loaded-BC hydrogels for wound 109 
management applications. Moreover, we discuss the effect of varied volume ratio of 110 
solvents to dissolve CUR and HPβCD on encapsulation efficacy during CUR:HPβCD 111 
inclusion complex (IC) formation using a solvent evaporation method. Qualitative and 112 
quantitative characterization performed on the CUR:HPβCD and CUR:HPβCD-loaded-BC 113 






far as the authors are aware, there are no studies reported in the literature on the 115 
production and characterization of CUR:HPβCD-loaded biosynthetic BC hydrogels for 116 
wound management applications.   117 
 
2. Materials and Methods 118 
2.1. Microorganisms, media and materials 119 
Gluconoacetobacter xylinus (ATCC 23770) and Staphylococcus aureus (NCIMB 120 
6571) were obtained from the University of Wolverhampton culture collection. Both 121 
microorganisms were maintained at -20 °C in a lyophilised form. Stock culture of G. 122 
xylinus was resuscitated on sterile mannitol agar (composition: yeast extract (5 g/L), 123 
peptone (3 g/L), mannitol (25 g/L), agar (15 g/L); all materials were purchased from 124 
Lab M, Bury, UK) and incubated for 48 h at 30 °C. Stock cultures of S. aureus were 125 
resuscitated on sterile tryptone soy agar (TSA) (Sigma-Aldrich, UK), prepared 126 
according to the manufacturer’s protocol and sterilised by autoclaving prior to use, 127 
and incubated for 48 h at 37 °C. Overnight broth cultures were aseptically prepared in 128 
suitable broth using the stock plates prior to experimental use. Bacteriological 129 
peptone, yeast extract and dextrose for the Hestrin and Schramm (HS) culture media 130 
were purchased from Lab M (UK). HS medium was prepared following the standard 131 
protocol [20]. Tryptone soya broth (TSB), disodium phosphate and citric acid were 132 
purchased from Sigma-Aldrich (UK). 133 
 
A549 lung adenocarcinoma, U251MG glioblastoma, MSTO mesothelioma and Panc 1 134 
pancreatic ductal adenocarcinoma were purchased from ATCC (UK). 135 
Hydroxypropyl-β-cyclodextrin (parenteral grade) was obtained from Roquette 136 
(France) and curcumin was purchased from Alfa Aesar (UK). Acetone was purchased 137 
from Fischer Scientific (UK). D2O was purchased from Goss Scientific (UK). Ringer 138 
solution (1/4 strength) tablets were purchased from Lab M (UK) and prepared by 139 
dissolving one tablet in 500 mL of de-ionised water and  sterilised prior to 140 
experimental use. Thiazolyl Blue Tetrazolium Bromide (MTT), sodium bicarbonate 141 
and 2,2-diphenyl-1-picrylhydrazyl (DPPH) were purchased from Sigma-Aldrich 142 
(UK). Dimethyl sulfoxide (DMSO), spectrophotometric grade, was purchased from 143 
Alfa Aesar (UK). Sodium hydroxide was purchased from Acros Organics (UK). NaCl 144 
(5.8 g/L) and glycine (7.6 g/L) were used for preparing Sorensen’s glycine buffer and 145 
purchased from Sigma-Aldrich, UK. Trypsin was purchased from Lonza (Belgium). 146 
Dulbecco’s Modified Eagle’s Medium (DMEM), Fetal Bovine Serum (FBS), L-147 
Glutamine and Antibiotic Antimycotic (10,000 units/mL penicillin, 10,000 µg/mL 148 






2.2. Preparation and characterisation of CUR:HPβCD inclusion complex 150 
 
2.2.1.  Preparation of CUR:HPβCD inclusion complex  151 
 152 
Inclusion complex of CUR with HPβCD was synthesised by the solvent 153 
evaporation (SE) method at the molar ratio of 1:1, following the protocol 154 
report by Yallapu, Jaggi, & Chauhan, (2010) [18], with appropriate 155 
modifications. In the current study, an attempt was made to prepare 156 
CUR:HPβCD inclusion complex by varying the volume ratio of solvents and 157 
evaluating the effect on encapsulation efficacy.  158 
 
Briefly, CUR (0.79 g) was dissolved in acetone (5 mL) and HPβCD (3.0 g) 159 
was dissolved in deionised water (45 mL). CUR solution was added dropwise 160 
to the aqueous HPβCD solution under constant stirring in a Schott bottle 161 
covered with aluminium foil. As the volume ratio of acetone to water was 10 162 
%, this sample was designated as IC 10. Similarly, using the same amounts of 163 
material (CUR 0.79 g and 3.0 g HPβCD) while varying the solvent volume 164 
ration, IC 25 (CUR in 12.5 mL acetone and HPβCD in 37.5 mL water); IC 50 165 
(CUR in 25 mL acetone: HPβCD in 25 mL water), IC 75 (CUR in 37.5 mL 166 
acetone: HPβCD in 12.5 mL water) and IC 90 (CUR in 45 mL acetone: 167 
HPβCD in 5 mL water) were prepared (Table. 1). Stirring was performed in a 168 
fume hood at room temperature for up to 72 h by replacing the lids of Schott 169 
bottles with perforated aluminium foil to allow acetone to slowly evaporate. 170 
Samples were then centrifuged at 3000 rpm for 10 min and the supernatant 171 
containing water soluble inclusion complex of CUR:HPβCD was collected. 172 
The resultant inclusion complex was filtered through a 0.45 µm filter 173 
(MILLEX
®
 HA, Merck Millipore) to remove any free CUR. The aqueous 174 
solution of ICs were then frozen at -20 °C overnight and lyophilised to obtain 175 
solid powders which were stored in dark for further experimental use. 176 
Table 1: Summary of the preparation of CUR:HPβCD inclusion complexes by varying 177 













Volume of water 
to dissolve HPβCD 
(mL) 




IC 10 0.79 3.00 5.00 45.00 10  
IC 25 0.79 3.00 12.50 37.50 25  
IC 50 0.79 3.00 25.00 25.00 50  
IC 75 0.79 3.00 37.50 12.50 75  






2.2.2.  Characterisation of CUR:HPβCD inclusion complex  179 
The formation of the inclusion complex was confirmed by testing its 180 
physicochemical properties. In addition to the studies presented in this section, 181 
further characterisations like morphological study by SEM, chemical 182 
characterisation by FTIR were undertaken which are presented in section 183 
2.3.3. 184 
2.2.2.1. Solubility study 185 
CUR, HPβCD and CUR:HPβCD  (10 mg each) were weighed and 186 
added to deionised water (10 mL) in separate universal tubes. These 187 
were stirred for 1 h at room temperature (22 °C) followed by 188 
filtration using 0.45 µm filter. An aliquot was taken for UV-Visible 189 
spectrophotometric scan between 350-650 nm. 190 
 
2.2.2.2. Determination of curcumin content and Encapsulation 191 
Efficiency (EE) 192 
CUR content in the inclusion complex was quantified by using UV-193 
Visible spectroscopy at a wavelength of 430 nm. The wavelength of 194 
430 nm is the λmax of CUR without any interference absorbance 195 
from HPβCD [21]. CUR:HPβCD (1 mg) was dissolved in dimethyl 196 
sulfoxide (DMSO) (5 mL) and gently shaken in an orbital shaker at 197 
150 rpm at 37 °C for 1 h to extract CUR. The solution was filtered 198 
through 0.45 µm filter and CUR content was determined by UV-199 
Visible spectroscopy at 430 nm. A standard calibration plot of CUR 200 
in DMSO was produced as a reference. The Encapsulation 201 
Efficiency (%) was determined using the formula:  202 
 
% 𝐸𝐸 =  
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 𝑐𝑢𝑟𝑐𝑢𝑚𝑖𝑛




2.2.2.3. X-ray diffractometric analysis (XRD) 205 
 
The X-ray diffraction patterns of CUR, HPβCD and CUR:HPβCD 206 
were obtained by an X-ray diffractometer (Empyrean, PANalytical, 207 
Neitherlands) with Cu radiation source. The X-ray diffractometer 208 








2.2.2.4.  Nuclear magnetic resonance (NMR) 210 
 





homonuclear correlation spectroscopy (COSY), heteronuclear single 212 
quantum correlation (HSQC), heteronuclear multiple bond 213 
correlation (HMBC), and rotating-frame nuclear Overhauser 214 
spectroscopy (ROESY) were performed on a 400 MHz JEOL NMR 215 
spectrometer JNM-ECZ400R/M1.  The sample consisted of 10-20 216 
mg of the inclusion complex dissolved in deuterium oxide. All 217 
spectra were internally referenced to residual solvent [22]. 
1
H 218 
spectra were acquired with a 45° pulse and inter-pulse delay of 5 219 
seconds across 16 transients with acquisition time of 2.18628 220 
seconds and pulse width of 6.48 µs; 
13
C NMR spectra were recorded 221 
with a 30° pulse and inter pulse delay of 5 seconds across 4097 222 
transients with acquisition time of 1.03809 seconds, and pulse width 223 
of 10.338 µs; HSQC spectra were recorded using a matrix consisting 224 
of 256 × 819 points across eight scans with a relaxation delay of 3 225 
seconds; HMBC spectra were recorded using a matrix consisting of 226 
512 × 1638 points across eight scans with a relaxation delay of 3 227 
seconds; COSY spectra were recorded by using a matrix of 1024 × 228 
1024 points across 1 scan with a relaxation delay of 3 seconds; 229 
ROESY spectra were recorded in a phase sensitive mode with 1024 230 
points in the x direction and 256 points in the y direction and 231 
acquired with 4 scans and relaxation delay of 1.5 seconds. Mixing 232 
time value was 0.25 seconds. 233 
 
2.2.2.5. Thermal gravimetric analysis (TGA) 234 
The evaluation of the thermal properties of CUR, HPβCD and 235 
CUR:HPβCD and physical mixture of CUR and HPβCD was 236 
undertaken using a Mettler Toledo Thermogravimetric Analyzer, 237 
TGA/DSC 1 STAR
®
 System. Samples were subjected to TGA from 238 
25 °C to 800 °C at 10 °C/min under constant flow of nitrogen (60 239 
mL per minute). Differential thermogravimetry (DTG) curve was 240 
also studied as a first derivative of TGA curve. 241 
 
2.2.2.6. Differential scanning calorimetry (DSC) 242 
DSC scans of CUR, HPβCD, CUR:HPβCD and physical mixture of 243 
CUR and HPβCD were performed using DSC Q2000 (TA 244 






aluminum pans (TA instruments) with a nitrogen flow rate of 50 246 
mL/min and temperature ramp rate of 20 °C/min. 247 
 248 
2.3. Preparation and characterisation of CUR:HPβCD-loaded-BC hydrogels 249 
2.3.1. Preparation of BC hydrogel pellicles 250 
Bacterial cellulose (BC) hydrogel pellicles were prepared and purified by the 251 
protocol reported previously [7]. Briefly, G. xylinus was selected for 252 
biosynthesis of BC and grown in the Hestrin and Schramm (HS) culture 253 
medium under static condition by incubation at 30
ᵒ
C for 14 days. 254 
Biosynthesised pellicles were harvested after this period and purified by firstly 255 
boiling in 1% (w/v) aqueous sodium hydroxide and subsequently in deionised 256 
water until the BC became clear and transparent.  257 
   
 
  
2.3.2. Loading CUR:HPβCD inclusion complex in BC hydrogel pellicles 258 
 
It is important to note that due to the highest encapsulation efficacy, IC 75 was 259 
selected for loading and further characterisation. Purified BC pellicles were 260 
padded dry using filter paper and loaded with IC 75 by immersing in 2 % 261 
(w/v) aqueous solution of CUR:HPβCD overnight under constant agitation at 262 
37
 
°C. Sterile conditions were maintained throughout the loading process. 263 
 
2.3.3. Characterisation studies 264 
 
CUR:HPβCD-loaded-BC hydrogels produced after loading the inclusion 265 
complex in padded dry BC were characterised to evaluate their properties for 266 
the potential wound dressing applications. 267 
 
2.3.3.1. Scanning electron microscopy (SEM) 268 
 
Solid samples of BC, CUR, HPβCD, CUR:HPβCD and lyophilised 269 
samples of CUR:HPβCD-loaded-BC were coated with gold using 270 
SC500 fine coater (Emscope, Kent, UK). The shape and 271 
morphology of these samples was studied using Zeiss Evo 50 EP, 272 






2.3.3.2. Fourier transform infrared (FTIR) spectroscopy 274 
 
FTIR of CUR, HPβCD, CUR:HPβCD and CUR:HPβCD-loaded-BC 275 
was recorded using a FTIR spectrophotometer (Bruker, Alpha, 276 
Platinum-ATR). The scanning range used was 400-4000 cm
-1
 with 277 
16 scans settings for each sample run. A background scan was run 278 
prior to the scan of samples to obtain spectra.  279 
 
2.3.3.3. Moisture content (Mc) 280 
 
The wet mass (Ww) of BC (neat BC hydrogels) and BC hydrogel 281 
pellicles loaded with aqueous solution of CUR:HPβCD (2 % w/v) 282 
was determined before lyophilisation and the dry mass (Wd) was 283 
recorded after lyophilisation. MC (%) was calculated using a 284 





 × 100 
 
2.3.3.4. Optical Transmission and Transparency test 286 
 
The quantitative optical transmission (%) of hydrogels was 287 
determined using LI-250A Light meter (LI-COR
®
 Biosciences). BC 288 
pellicles were padded dry and rehydrated either with deionised 289 
water (neat BC) or 2 % (w/v) aqueous solution of CUR:HPβCD (test 290 
hydrogels) and optical transmission (% T) of light was read. 291 
Readings were taken for petri dish with deionised water (control), 292 
neat BC pellicles in petri dish and test BC pellicles. Four readings 293 
from a different sections of each neat and test BC pellicles were 294 
recorded and averages used to examine the % T by comparison to 295 
the control (100 % T).   296 
 
Moreover, the neat and 2 % CUR:HPβCD-loaded-BC hydrogels 297 
were transferred on the laminated paper with text in different 298 
colours. The clarity of letters beneath each hydrogel was examined 299 
to determine if it would permit observation and assessment 300 







2.3.3.5. Water vapour transmission rate (WVTR) 302 
The WVTR of neat BC and CUR:HPβCD-loaded-BC hydrogel 303 
dressings was measured using the cup test method according to the 304 
American Society for Testing and Materials (ASTM) standard 305 
[23,24]. In the current study, to achieve controlled conditions with 306 
minimum variations in set parameters during the entire length of the 307 
experiment, hypoxia incubator (Optronix, Oxford, UK) was used 308 
instead of saturated salt chamber as reported previously [25]. An 309 
incubator temperature of 35±0.1 °C and 60±1 % relative humidity 310 
[RH] was maintained using compressed air during the entire period 311 
of the experiment. There was no attempt to artificially adjust air 312 
flow in the chamber as the influence of local air velocity was not 313 
examined in this study. A digital balance (ON BALANCE
TM
, Myco 314 
MZ-100-BK) was placed inside the chamber for weighing the 315 
assemblies. The selected temperature (35 °C) corresponds to the 316 
temperature of the wound site as reported by Lamke et al., 1977 317 
[26].  318 
Purified BC pellicles were padded dry and rehydrated either with 319 
deionised water (neat BC) or 2 % (w/v) CUR:HPβCD aqueous 320 
solution (test hydrogels) under agitated conditions at 150 rpm and 321 
37 °C overnight in an orbital shaker. Thickness of the rehydrated BC 322 
pellicles was measured using a Vernier calliper (Whitworth Digital 323 
calliper).  Four readings for each pellicle were taken and average 324 
thickness calculated. Neat BC and/or CUR:HPβCD-loaded-BC 325 
hydrogels (2.44 cm exposed diameter) were secured onto glass 326 
vessels containing 7.5 mL distilled water. The assemblies were kept 327 
in the chamber in upright position. WVTR was determined (in 328 
triplicates) by weighing the complete beaker assembly inside the 329 
chamber at set time intervals and calculated as [27]: 330 
𝑊𝑉𝑇𝑅 =
𝑠𝑙𝑜𝑝𝑒 x 24
𝑡𝑒𝑠𝑡 𝑎𝑟𝑒𝑎 𝑖𝑛 𝑚2
 𝑔/𝑚2/𝑑𝑎𝑦 
 
2.4. In vitro tests of CUR:HPβCD-loaded-BC hydrogels 331 
2.4.1.  Haemocompatibility 332 
  
In the current study, with the intended wound management applications, the 333 
haemocompatibility of CUR:HPβCD-loaded-BC hydrogels was evaluated in 334 
vitro, by assessing haemolytic potential of hydrogels. The test was performed 335 
as previously reported for testing haemocompatibility of BC with some 336 






TCS Biosciences Ltd) was washed with sterile 0.9 % saline (pH 5.5) twice and 338 
centrifuged at 3000 rpm for 10 min before re-suspending in saline solution. 2 339 
% (w/v) CUR:HPβCD was prepared in saline and loaded in padded dry BC 340 
pellicles.  Using the biopsy punch, CUR:HPβCD-loaded-BC discs (≈8.0 mm) 341 
were cut and incubated with 1.9 mL saline-suspended horse blood cells in test 342 
Eppendorfs under sterile conditions. Positive (+ve) controls were distilled 343 
water suspended blood cells and negative (-ve) controls were blood cells 344 
suspended in saline. Eppendorfs were incubated at 4 °C for 2 h with gentle 345 
inversion after every 15 min. Post-incubation, BC discs were removed under 346 
sterile condition followed by each sample being centrifuged at 3000 rpm for 347 
10 min and supernatant decanted. Absorbance was recorded at 540 nm and 348 
percentage (%) haemolysis was determined as follows: 349 
 
% 𝐻𝑎𝑒𝑚𝑜𝑙𝑦𝑠𝑖𝑠 =
(𝐴𝑏𝑠 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒) − (𝐴𝑏𝑠 𝑜𝑓 − 𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙)




2.4.2.  Cytocompatibility (in vitro cell viability) 350 
Cytocompatible nature of BC has been previously reported [25]. To study the 351 
effect of the CUR:HPβCD-loaded-BC on cell viability, the previously reported 352 
study was extended on 4 human cancer cell lines from different tissues, 353 
namely, A549 (human lung adenocarcinoma), MSTO (human mesothelioma), 354 
PANC1 (human pancreatic ductal adenocarcinoma) and U251MG (human 355 
glioblastoma).  356 
All cell lines were cultured in DMEM medium containing 4.5 g/L glucose, 357 
supplemented with fetal bovine serum (10 %), Antibiotic Antimycotic (1 %), 358 
L-Glutamine (2 mM) and incubated at 37 °C in a humidity incubator with 5 % 359 
CO2. The cytocompatibility of free CUR:HPβCD and CUR:HPβCD-loaded-360 
BC was investigated. Four different concentrations of CUR:HPβCD (1 %, 1.25 361 
%, 1.5 %, 2 % w/v) were prepared in Dulbecco’s Modified Eagle’s Medium 362 
(DMEM). BC pellicles were padded dried and either rehydrated with DMEM 363 
(control) or the respective concentrations of CUR:HPβCD in DMEM (test) in 364 
an orbital shaker at 37 °C at 150 rpm for overnight. Discs (≈8.0 mm diameter) 365 
were cut from the control and test pellicles using a corer for the experimental 366 
purposes. The whole procedure was conducted aseptically.  367 
Briefly, 25,000 cells per well were seeded in 24 well plates for 24 h at 37 °C in 368 
5% CO2 incubator. The cells were then exposed to either free CUR:HPβCD or  369 
CUR:HPβCD-loaded-BC discs for 24 h. After incubation, the morphology of 370 
cells, confluence of the cell monolayer and cell viability was observed 371 






of free CUR:HPβCD and CUR:HPβCD-loaded-BC discs on  cell viability was 373 
evaluated by standard MTT cytotoxicity assay by adding 5 mg/ml MTT 374 
solution (Sigma, UK) in all the wells and incubated for 2 h, followed by 375 
solubilising the formazan crystals with DMSO and Sorensen’s glycine buffer 376 
(pH 10.5). All experiments were done in triplicates and cell viability was 377 
calculated using the mean absorbance measured at 540 nm and the results were 378 
statistically analysed by two-way ANOVA with a Tukey’s multi comparisons 379 
test using GraphPad Prism.   380 
   
2.4.3.  Curcumin release study  381 
 
Small (≈8.0 mm diameter) sized discs of purified BC were cut using a biopsy 382 
punch and padded dry on filter paper. These discs were loaded with 2 % (w/v) 383 
aqueous solution of CUR:HPβCD by incubating overnight at 37 °C in glass 384 
Bijoux bottles, under agitated conditions at 150 rpm.  385 
  
These discs were transferred to individual Bijoux tube containing 1 mL 0.9 % 386 
saline (pH 5.5) and incubated under static conditions at 35 °C. At set intervals, 387 
discs were moved to a new set of bijoux tubes with fresh 1 mL saline and 388 
incubated under same conditions. This was repeated over 48 h and CUR 389 
release was spectroscopically assessed at 430 nm for each time interval.  390 
 391 
The standard calibration curve of CUR in 0.9 % saline (pH 5.5) was produced 392 
as a reference. Briefly, the stock solution (1000 µg/mL) of CUR was prepared 393 
by taking CUR (10 mg) and dissolving in ethanol:saline (70:30 % v/v) and 394 
making up to 10 mL. A standard solution (30 µg/mL) was prepared by taking 395 
150 µL of stock solution and making up to 5.0 mL using saline. Using this 396 
standard solution, other standards were prepared in saline and the standards 397 
were read at 430 nm using saline as blank.  398 
 399 
2.4.4.  Antimicrobial activity by disc diffusion assay: 400 
 
The antimicrobial activity of BC loaded with 2 % (w/v) aqueous CUR:HPβCD 401 
was investigated against S. aureus, using the disc diffusion assay; purified BC 402 
and BC loaded with HPβCD were used as controls. Discs of BC, BC-HPβCD 403 
and BC-CUR:HPβCD (≈8.0 mm diameter) were aseptically cut and placed on 404 
TSA plates spread with overnight culture of S. aureus and following 405 
incubation at 37 °C for 24 h, the zone of inhibition (ZOI) was measured. 406 
Results are presented for ZOI (mm) at 24 h and analysed by one-way ANOVA 407 
with a Tukey’s multi comparisons test using GraphPad Prism. 408 
 
 







2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging assay was 410 
performed according the protocol reported by [28] with appropriate 411 
modification. Briefly, test solutions of varying concentrations of CUR:HPβCD 412 
in methanol were prepared and methanol was used in preparing a blank. The 413 
assay mixture with 1 mL DPPH (80 µg/mL) methanolic solution and 1 mL 414 
solutions of various concentrations of the material (including a blank) after 415 
mixing were incubated in dark for 30 min at room temperature. Absorbance 416 
was measured spectrophotometrically at 517 nm. The free radical scavenging 417 
capacity was calculated as percent antioxidant effect (% E) using the following 418 
equation. Different sample concentrations were used to produce a curve for 419 
calculating IC50 values, the amount of sample required to obtain 50 % of the 420 
free radical inhibition [29]. 421 
 422 
%𝐸 =











3. Results and discussion 425 
3.1. Preparation of CUR:HPβCD-loaded-BC hydrogels 426 
G. xylinus produced BC hydrogel pellicles in 2 weeks under static conditions. These 427 
pellicles were harvested and purified to get rid of entrapped bacterial cells and excess 428 
media. The hydrogel pellicles after purification became clear and transparent (Fig. 1a) 429 
which is in accordance with our previous study [7]. The BC pellicles after purification 430 
were ready for loading with CUR:HPβCD.  431 
CUR:HPβCD (yellow powder) was produced from the CUR (dark yellow powder) 432 
and HPβCD (white powder) by solvent extraction method which is in accordance with 433 
the literature [18]. The novel approach taken in this study to produce IC 10, IC 25, IC 434 
50, IC 75 and IC 90, supramolecular inclusion complexes revealed that varied solvent 435 
volume ratios have an influence on CUR content encapsulated in HPβCD. The EE 436 
(%) results of IC 10, IC 25, IC 50, IC 75 and IC 90 revealed 3.64±0.16 %, 3.84±0.37 437 
%, 7.37±1.24 %, 18.26±1.02 % and 16.34±0.75 % (n=3) encapsulation efficacy 438 
respectively. These results suggested that IC 75 produced by CUR dissolved in 37.5 439 
mL acetone and HPβCD dissolved in 12.5 mL water for the inclusion complex 440 
production gave highest % EE hence it was selected as a standard procedure for the 441 
preparation of inclusion complex for further experimental investigations. It is 442 
important to note that all the characterisations for CUR:HPβCD were done using IC 443 
75. CUR content determined in IC 75 samples was in the range of 3.28±0.38 % (n=4).   444 
IC 75 was loaded in padded dry BC to produce hydrogels for wound management 445 
applications. Visual inspection of purified BC hydrogel pellicles loaded with 2 % 446 
(w/v) CUR:HPβCD revealed highly consistent loading (Fig. 1b). After loading of the 447 
inclusion complex, the colour of BC hydrogels changed from clear to orange yellow 448 










Figure 1: Visual appearance of (a) BC hydrogel pellicle after purification 







3.2. Characterisation studies of CUR:HPβCD inclusion complex and CUR:HPβCD-459 
loaded-BC hydrogels 460 
 
3.2.1. Solubility in water: CUR versus CUR:HPβCD inclusion complex 461 
CUR exhibits the maximum absorbance at ≈430 nm [30]. In the current study, 462 
the inclusion of CUR in HPβCD enhanced its aqueous solubility which was 463 
evident in the spectral scan (Fig. 2). The UV-Visible spectrum of aqueous 464 
filtrate of CUR didn’t exhibit significant absorption in the specified spectral 465 
range suggesting low aqueous solubility of CUR at the aforesaid conditions. 466 
Moreover, the aqueous solution of HPβCD didn’t show significant absorbance 467 
in the selected range. In case of the CUR:HPβCD, there was strong 468 
absorbance recorded around 430 nm due to enhanced aqueous solubility of 469 
CUR. These results correspond with previous studies that CUR has poor 470 











   
 
  473 




















Figure 2: UV-Visible absorption spectra of CUR, HPβCD and 
CUR:HPβCD dissolved in water after 1 h stirring at room temperature 






3.2.2.  X-ray Diffractometric analysis (XRD) 475 
The XRD spectra of CUR, HPβCD and lyophilised CUR:HPβCD are shown in 476 
Fig. 3. Results revealed that CUR exists in a crystalline form which is 477 
indicated by the characteristic peaks (Fig. 3a) whereas HPβCD is amorphous 478 
(Fig. 3b) in nature. After complexation with HPβCD, there was no noticeable 479 
evidence of crystallinity of CUR in the inclusion complex (Fig. 3c). This 480 
suggests that CUR may have formed an inclusion complex with HPβCD 481 
leading to the loss of peaks. These results are in accordance with literature 482 













3.2.3. Nuclear Magnetic Resonance spectroscopy (NMR) 485 
 
NMR spectroscopy was used to investigate the success of the formation of the 486 
inclusion complex between hydroxypropyl-β-cyclodextrin and curcumin 487 




C NMR data of the CUR:HPβCD was assigned 488 
using a combination of previously reported proton NMR data [35] and 2D 489 




C NMR data in 490 
Fig. S2-S5 in the supporting information). 491 
 
Evidence for the formation of the CUR:HPβCD inclusion complex can be 492 
chiefly observed through both 
1
H and ROESY NMR. Upon inspection of the 493 
1
H NMR spectra, CUR:HPβCD displayed a distinctive upfield shift in the 494 




 of 495 
HPβCD upon inclusion of CUR in comparison to the neat HPβCD; the 496 






















resonances of the externally facing protons of CUR:HPβCD remained 497 
unchanged (Fig. S6 and S7; see Scheme S1a-c for structural assignments in 498 
the supporting information). This indicates a change in the local magnetic 499 
environment of the HCβCD protons in the presence of the CUR aryl/alkenyl 500 
group(s).  501 
 
Further conclusive evidence for the formation of CUR:HPβCD was 502 
subsequently obtained by ROESY NMR analysis; a ROESY correlation 503 
between H
5
 of HPβCD and CUR aryl protons spectrum clearly indicates the 504 





Figure 4: Expansion of the ROESY spectrum of the CUR:HPβCD inclusion complex 508 
in D2O indicating correlation cross peaks between HPβCD and CUR (inset: schematic 509 
structure of the inclusion complex). 510 
 
3.2.4. Thermal Analysis (TGA and DSC) 511 
The thermal analytical techniques like TGA and DSC are widely used in pre-512 
formulation studies. The thermokinetic data could be used to understand the 513 
thermal decomposition reaction and helps determine the storage conditions. 514 






mixture and the CUR:HPβCD inclusion complex could provide evidence of 516 
interactions between compounds and the formation of inclusion complex [36].  517 
Thermal behaviour of CUR, HPβCD, CUR:HPβCD was investigated and 518 
compared to CUR and HPβCD physical mixture, to understand the solid-state 519 
characterisation and thermal stability of the inclusion complex during 520 
production and storage. Thermogravimetric data revealed that thermal 521 
degradation of CUR starts at around 220
 
°C, which is ≈ 40 °C above its 522 
melting point. It loses around 54 % mass between 300-420 °C. HPβCD mass 523 
loss of nearly 6 % at around 91 °C attributed to the loss of water and major 524 
mass loss (>70 %) peaks at 344
 
°C due to the decomposition of the molecule 525 
(Fig. 5a-b).  These weight losses were visible in both, the physical mixture and 526 
CUR:HPβCD inclusion complex. On further examination, it was noticed that 527 
the inclusion complex displayed higher thermal stability as shown in Fig. 5a-b 528 
but as our study aims at the application of the product at the physiological 529 
temperature so the decomposition at high temperatures (>300 °C) was not 530 
significant. It should be noted that due to the inclusion of CUR in HPβCD 531 
cavity, the thermal behaviour of CUR was different from free CUR which is in 532 
accordance with literature [36].  533 
The thermokinetic data did not show decomposition at normal working 534 
temperatures suggesting that the production and storage of the inclusion 535 
complex at room temperature does not affect its thermal stability. BC is 536 
thermally stable at the standard autoclaving temperatures [25]. The data from 537 
the current study suggests that the inclusion complex is also thermally stable at 538 
such temperatures. Since BC and the inclusion complex are both thermally 539 
stable at the standard autoclaving temperatures, the hydrogel dressings may be 540 
sterilised by autoclaving prior to the application on the wound site.   541 
DSC analysis was performed to further corroborate the results obtained from 542 
TGA. DSC results of CUR revealed an enthalpy change with a sharp 543 
endotherm in the region of 179
 
°C indicative of its melting point (Fig. 5c). In 544 
the case of HPβCD, there was observed two endotherms around 259
 
°C and 545 
291
 
°C followed by its decomposition (Fig. 5c). In the case of physical 546 
mixture, the characteristic endotherms of CUR appeared at 179
 
°C suggesting 547 
free CUR in the physical mixture. Moreover, endotherm peaks attributed to 548 
HPβCD were also visible. However, shift in peak positions was observed (Fig. 549 
5c) which could be due to the interactive effect of HPβCD with CUR on 550 
mixing, which is in accordance with literature findings [19]. The thermogram 551 
of CUR:HPβCD revealed that the melting endotherm peak for CUR in the 552 
inclusion complex disappeared, suggesting that CUR was protected up to 244 553 
°C. Moreover, the shift in endotherm peaks attributed to HPβCD in 554 






interactions of inclusion of CUR in the HPβCD cavity (Fig. 5c) thus indicating 556 







Figure 5: (a) TGA curves (b) DTG curves (c) DSC spectra of CUR, HPβCD, CUR, 




























































3.2.5. Scanning electron microscopy (SEM) 559 
 560 
BC appears as a dense interwoven fibre network [7]. It emerged that the fine 561 
ribbons (30-105 nm thickness) (Fig. 6a) of cellulose entangle with each other 562 
forming the network structure interspersed with voids. Morphological studies 563 
of lyophilised purified BC revealed two types of pores in the BC network 564 
structure; nano pores with pore size as low as 27 nm (Fig. 6b) and some large 565 
superficial pores with diameter value of up to 10 µm (Fig. 6c). It may be noted 566 
that these pores may further expand on hydration with water. SEM results 567 
revealed that the shape of CUR and HPβCD changed from round to irregular 568 
shape to plate like structures in CUR:HPβCD (Fig. 6d-f). When padded dry 569 
BC was rehydrated by immersion in aqueous solution of CUR:HPβCD, the 570 
voids allowed penetration of the inclusion complex which then got physically 571 
entrapped in the BC fibre network (Fig. 6g). This resulted in the production of 572 
CUR:HPβCD-loaded-BC hydrogels. 573 






  575 
Figure 6: SEM images of (a - c) BC morphology with fibre thickness and pore size 











3.2.6. Fourier transform infrared (FTIR) 576 
A detailed investigation on the vibrational spectra of CUR, HPβCD and BC 577 
has been reported in literature [7,19,32]. FTIR spectral results of CUR, 578 
HPβCD, CUR:HPβCD, purified BC and CUR:HPβCD-loaded-BC are 579 
illustrated in Fig. 7. The characteristic sharp peak at 3504 cm
-1
 and a broad 580 
peak at band regions of 3308 cm
-1
 suggested the presence of OH; 1619 cm
-1 
581 
was assigned to C=C and C=O vibrations; 1591 cm
-1
 to the stretching 582 
vibrations of benzene ring and 1497 cm
-1
 to the C=C (Fig. 7a). For HPβCD the 583 
characteristic broad peak at 3340 cm
-1
 was assigned to stretching vibrations of 584 
OH group; 2927 cm
-1
 to C-H stretching and other prominent peaks presented 585 
at 1156 cm
-1
 and 1084 cm
-1
 (C-H), 1024 cm
-1
 (C-O-C glucose units) (Fig. 7b). 586 
In CUR:HPβCD, due to the encapsulation of CUR in HPβCD cavity, the peaks 587 





appeared to be masked by HPβCD molecular vibrations in the 589 
inclusion complex (Fig. 7c) which could be due to the inclusion of CUR in 590 
HPβCD cavity [19,31,32].  591 













(Fig. 7d). These peaks appeared in CUR-HPβCD-593 
loaded-BC spectra (Fig. 7e). Furthermore, the characteristic peaks of the 594 
inclusion complex were also observed in the spectra (Fig. 7e), thereby 595 













Figure 7: FTIR spectra from 400-4000cm
-1
 for (a) CUR (b) HPβCD (c) CUR:HPβCD (d) bacterial 






























































3.2.7. Moisture content (Mc) 597 
BC hydrogels have high water content and the results of the moisture content 598 
determination study revealed neat BC hydrogels imbibed >99.5 % (n=4) water 599 
which is accordance with previously published data [25]. Moreover, the results 600 
revealed that BC loaded with 2 % (w/v) CUR:HPβCD imbibed 97.63±0.057 % 601 
(n=4) water. These results suggested that CUR:HPβCD inclusion complex that 602 
gets physically trapped in BC fibres (as suggested in Fig. 6g) contributes to 603 
this difference between neat BC and CUR:HPβCD-loaded-BC.  604 
Wound dressings with high moisture content offers several benefits including, 605 
but not limited to, high malleability, easy and pain free removal of the 606 
dressing, cooling and soothing effect resulting in a sensation of pain reduction 607 
with a capability of developing a moist microclimate that has been proven to 608 
enhance epithelialisation [1,3,5,37,38]. The high moisture content in 609 
CUR:HPβCD-loaded-BC hydrogels produced in the current study would 610 
deliver these beneficial attributes and contributes towards facilitating wound 611 
healing along with patient comfort and compliance.  612 
 
3.2.8. Optical Transmission and Transparency test 613 
 
The appearance of the wound site is vital to assess patients’ response to the 614 
treatment. A basic technique to carry out this assessment is by visual 615 
observation of the wound site by the removal of the dressing, however removal 616 
of the dressing from the wound site could cause trauma [3]. Non-invasive 617 
monitoring of the healing process without the need to remove the wound 618 
dressing has the potential to ensure effective management [39]. This would 619 
allow regular clinical assessment of the wound healing process, improve 620 
patient comfort and potentially lower the cost of treatment with less frequent 621 
dressing change.  622 
 
Transparency is a property that measures the ability of the material to allow 623 
the light pass through without scattering [40]. In the current study an attempt 624 
was made to produce the hydrogel dressings delivering this feature. Neat BC 625 
hydrogels demonstrated the % Transmission of 85.72±1.57 % (n=3). 626 
Although, the light transmittance of CUR:HPβCD-loaded-BC hydrogel 627 
dressings was reduced, this is sufficiently high (66.13±2.36 %) (n=3).  628 
 
On further evaluation, the clarity of letters through the hydrogels supported 629 
high transparency through both the neat and CUR:HPβCD-loaded-BC 630 
hydrogels (Fig. 8). These results support the capability of CUR:HPβCD-631 






Several protocols have been reported in the literature to evaluate the 633 
transparency of hydrogels with wound dressing applications [37,41]. The 634 
authors are mindful that the method designed and employed in the current 635 
study for transparency testing may not exactly mirror the real wound site; for 636 
that to be considered, this study could be extended to in vivo animal models. 637 

















3.2.9. Water Vapour Transmission Rate (WVTR) 641 
Normal skin has the ability to control the water loss by evaporation from the 642 
body, to prevent dehydration, which gets compromised when the integrity of 643 
the skin is affected by injury. Lamke, Nilsson, & Reithner, 1977 [26] reported 644 
the evaporation water loss of 204±12 g/m
2
/24 h from the normal skin which 645 
could go up to 5138.4±201.6 g/m
2
/24 h in case of a granulating wound. 646 
An ideal wound dressing material must have a property to control the 647 
evaporative water loss from the wound [24]. High WVTR may lead to 648 
dehydration and scab formation whereas very low WVTR may lead to the 649 
accumulation of exudate, maceration of periwound skin and increased risk of 650 
infections [38].  651 
In the current study, WVTR was evaluated as the gradient of weight loss from 652 
the samples versus time. The thickness of rehydrated hydrogels (neat and test) 653 
was in the range of 1.5-2.5 mm. WVTR values for neat BC were in the range 654 
of 2526.32-3137.68 g/m
2
/24 h (n=3) and for 2 % CUR:HPβCD-loaded-BC 655 
were 2258.53-2460.63 g/m
2
/24 h (n=3). Previous reported studies suggest that 656 
a WVTR level of 2000-2500 g/m
2
/24 h would be sufficient to maintain an 657 
optimum moist environment at the wound site [24,25,42]. Our results revealed 658 
that the WVTR range of CUR:HPβCD-loaded-BC hydrogels were close to the 659 







recommended range hence would be suitable for wound healing applications.  660 
Moreover, the results revealed that the loss of water from neat BC hydrogels 661 
was more than from the test hydrogels (CUR:HPβCD-loaded-BC). We 662 
postulated this is due to the CUR-HPβCD loaded in the BC network structure 663 
reducing the void space in the hydrogels and controlling the transmission of 664 
water in CUR:HPβCD-loaded-BC hydrogels compared to neat BC.  665 
 
3.3. In vitro characterisation of CUR:HPβCD-loaded-BC hydrogels 666 
3.3.1. Biocompatibility studies (Haemocompatibility and Cytocompatibility) 667 
When materials come in contact with blood, they may cause haemolysis of the 668 
blood cells thus assessment of haemolytic properties become vital for 669 
materials with potential biomedical applications. According to the ASTM 670 
F756 standards [43], haemolytic indices, the test samples can be: (a) 671 
haemolytic materials with haemolysis >5 % (b) slightly haemolytic with 672 
haemolysis between 2-5 % and (c) non-haemolytic materials having 673 
haemolysis below 2 % [44]. The in vitro blood compatibility results revealed 674 
that the test hydrogels are haemocompatible with % haemolysis <0.20 % 675 
(n=9) which is well below the acceptable limit for haemolysis. These results 676 
confirmed that CUR:HPβCD-loaded-BC hydrogels are non-haemolytic 677 
material and suitable for wound management applications.  678 
BC has been reported to be cytocompatible for biomedical applications 679 
[25,37]. Cytocompability is one of the many properties of BC leading to its use 680 
in fabricating proprietary wound dressings. High bacterial burden at the wound 681 
site has deleterious effect on the wound healing hence the use of antimicrobial 682 
becomes imperative. Since bacteriostatic and/or bactericidal agents may have 683 
harmful effect on the host cells, therefore a benefit:risk ratio has to be 684 
evaluated for the selection of antimicrobial wound dressings [45]. The use of 685 
proprietary silver dressings in chronic wound management to control the 686 
microbial bioburden is a good example where the benefit outweighs the risk of 687 
cytotoxic effect of silver [45,46]. In the current study, the MTT 688 
cytocompatibility study aims to find out how the CUR released from the 689 
hydrogels affects the survival of mammalian cells. The cytotoxicity as 690 
determined by MTT assay demonstrated that the CUR:HPβCD-loaded-BC 691 
hydrogels has varied compatible with the tested cell lines (Fig.  9a). Despite 692 
the varied response, all cell lines demonstrated cell viability when exposed to 693 
CUR:HPβCD or CUR:HPβCD-loaded-BC hydrogels (Fig. 9a-c). Four 694 
different cell lines were used in this study and most of them tolerated up to 2% 695 
CUR:HPβCD over 24hrs and showed very good survival rates. Despite being 696 
very sensitive, the A549 cell line also showed around 60 % survival at the 697 






survival in comparison to control, this dose has not even reached the standard 699 
IC50/50% cell death to define this as a highly toxic effect. Moreover, in 700 
patients, this will correspond to how much free CUR is being released from 701 
the material and get in the systemic circulation. It is very unlikely that this 702 
amount will cause the toxic effect to vital organs.  703 
 704 
Furthermore, we compared the cytocompatibility of CUR:HPβCD-loaded-BC 705 
hydrogels with that of free CUR:HPβCD (equivalent amount). The results 706 
showed that there was no significant difference (p>0.05) between the free 707 
CUR:HPβCD or the 2 % CUR:HPβCD-loaded-BC hydrogels. This indicated 708 
that the BC matrix used to deliver CUR:HPβCD inclusion complex does not 709 
affect the cell viability.  710 
 
Our results are in accordance with other cytotoxicity studies reporting the 711 
cytocompatible nature of CUR and its conjugates for biomedical applications 712 
[47-49]. These findings further support the potential wound dressing 713 






























































































































































































































































3.3.2. CUR release and Antimicrobial study 720 
 
CUR release from CUR:HPβCD-loaded-BC hydrogels, as determined by UV-721 
Vis spectroscopy, is presented in Fig. 10. Results indicate that 76.99±4.46 % 722 
release (n=6) was achieved after 6 h from CUR:HPβCD-loaded-BC hydrogels. 723 
The release was slow after this duration and reached 79.36± 4.71 % at 24 h. 724 
The maximum release achieved at 48 h was 82.19±4.75 % confirming high 725 
bioavailability of CUR:HPβCD at the wound site to control bacterial infection 726 


















After the release profile was evaluated, the disc diffusion assay was 730 
undertaken to assess the antimicrobial activity of CUR:HPβCD-loaded-BC 731 
hydrogels. The results revealed no anti-microbial activity against S. aureus 732 
(Gram positive) for neat BC and HPβCD-loaded-BC which is in accordance 733 
with literature [7,25,50,51]. However, CUR:HPβCD-loaded-BC hydrogels 734 
demonstrated significant (p<0.01) antimicrobial activity (Fig. 11) (ZOI= 735 
11.08±0.90 mm) (n=12) compared to neat BC and HPβCD-loaded-BC. CUR 736 
is well known for its antimicrobial properties against a broad range of 737 
microorganisms [52-54]. Its antimicrobial activity ensues due to its ability to 738 
interact with an essential prokaryotic cell division initiating protein (FtsZ) 739 
Figure 10: Release profile over 48 h from CUR:HPβCD-loaded-BC 






















Figure 9: Cytocompatibility test results.  Bar graphs showing viability of different cells after 24 
h exposure to (a) free CUR:HPβCD and 2 % CUR:HPβCD-loaded-BC. Representative optical 
photomicrographs of cells captured at 10x magnification after exposure for 24 h to (b) free 






[54,55]. Moreover, it has been identified to possess inhibitory effect against 740 
sortase A, a membrane-associated transpeptidase that plays a crucial role in 741 
modulating the ability of Gram-positive bacteria (including S. aureus) to 742 
adhere to the host tissue and cause infection [53]. The disc diffusion results 743 
confirmed that CUR maintained it antimicrobial feature even after 744 
encapsulation in the HPβCD cavity demonstrating the potential use of 745 














3.3.3. Anti-oxidant activity by DPPH assay 750 
Oxidative stress has been identified, through preclinical and clinical studies, as 751 
one of the major causes of nonhealing in chronic wounds [56]. CUR is 752 
reported as a potent antioxidant due to its ability to reduce reactive oxygen 753 
species such as super oxide radicals, lipid peroxyl radicals and hydroxyl 754 
radicals [10,57]. Its antioxidant activity arises due to its ability to undergo H-755 
atom abstraction from its phenol groups giving rise to a stable, delocalised 756 
radical species [56]. Several methods have been adopted to assess the free 757 
radical scavenging potential of anti-oxidant substance and the DPPH assay is 758 
still one of the routinely practiced method for this assessment. In the current 759 
study, the antioxidant activity of CUR:HPβCD was assessed by this assay. The 760 
reaction of DPPH radicals with antioxidant is a kinetic driven process which 761 
varies for different antioxidants. In the current study, a fixed reaction time 762 
mode of 30 min was adopted for estimation of the antioxidant activity [58].  763 
Figure 11: Antimicrobial activity assessed by ZOI during the disc diffusion 
assay for neat BC hydrogel, HPβCD-loaded-BC and CUR:HPβCD-loaded-


































The percent antioxidant effect for supramolecular CUR:HPβCD against DPPH 764 
determined in the current study ranged from 12.06±0.014 - 79.75±0.001 % in 765 
the range of 125-2000 µg/mL and the IC50 was found to be 1087.49±6.47 766 
µg/mL (n=3). It was found that HPβCD does not have antioxidant activity and 767 
our results are in agreement with literature [59]. These finding confirmed that 768 
the antioxidant activity of CUR stays preserved even after its encapsulation in 769 
HPβCD cavity in the CUR:HPβCD inclusion complex. These findings are in 770 
accordance with Aytac & Uyar (2017) [34]. These results advocate the 771 
antioxidant potential of BC hydrogels loaded with CUR:HPβCD to reduce the 772 
oxidative stress at the impaired wound site.  773 
 
4. Conclusion: 774 
The present study demonstrates the production, physicochemical characterisation, in vitro 775 
biocompatibility and antimicrobial performance of biosynthetic CUR:HPβCD-loaded-BC 776 
hydrogels for potential wound management applications. The physicochemical 777 
characterisation confirmed the formation of IC of CUR:HPβCD with enhanced aqueous 778 
solubility compared to free CUR. Varying the solvent volume ratios during the solvent 779 
evaporation method, IC 75 emerged to be the best preparation method with the highest 780 
encapsulation efficacy. The CUR:HPβCD-loaded-BC hydrogels demonstrated high light 781 
transmission, a property that has a potential of clinical wound monitoring without the need 782 
to remove the dressing. Moreover, these hydrogels offer optimum WVTR that could help 783 
maintain the moist environment at the wound site. Their high moisture content, 784 
biocompatibility (cytocompatibility and haemocompatibility), antimicrobial and 785 
antioxidant properties advocates their potential application as hydrogel dressings for 786 
chronic, infected wound management. These findings suggest that biosynthetic 787 
CUR:HPβCD-loaded-BC hydrogels could represent an alternative in the dressing 788 
landscape for wound management. 789 
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Figure S1 b: Chemical structure and a truncated cone schematic of hydroxylpropyl-β-1004 
cyclodextrin (HPβCD). Annotations for NMR assignments are shown on one glucose 1005 











S1 c: The schematic representation of CUR:HPβCD inclusion complex. Through space 1012 





) and the aryl CH groups of CUR (Hc, Hd and He). Note: only one of seven 1014 





NMR analysis of inclusion complex 1020 
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Figure S7: Expansion overlay of 
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H spectra of HPβCD and the CUR:HPβCD inclusion 1055 
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 1057 
 1058 
 
